A phase 1/2 trial of DB-1324 in advanced solid tumours, run by DualityBio Inc., now recruiting.
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors is a phase 1/2 interventional study registered as NCT07263594 by DualityBio Inc., with 127 participants planned, started 2026-01-20 and due to reach its primary completion in 2028-12. Interventions recorded: DB-1324.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Duality Biotherapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.